Article
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortalit
Rating:
0.0
Views:
81
Likes:
1
Library:
1
About two and a half months after the FDA turned away their lead program, Mesoblast $MESO reported a Phase III miss Monday afternoon for their second clinical product. But the Australian biotech pointed toward data in a secondary endpoint it thinks the agency might
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value